|
|
Article: Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection.
- Article from:
- Health & Medicine Week
- Article date:
- May 19, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Par Pharmaceutical Companies, Inc. (NYSE:PRX) announced that it amended its agreement with Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for $20 million in cash to increase its share of profits from the generic versions of GlaxoSmithKline's Imitrex(R) Injection, which will be immediately accretive to 2008 earnings and provide a strong return on the Company's investment. As a result of the agreement, Par's profit share will increase from 38% to 95% from the commercialization of sumatriptan injection. Imitrex Injection (sumatriptan succinate injection) is used for the acute treatment of migraine attacks with or without aura, and the acute treatment of cluster headache ...
Related newspaper, magazine, and journal articles:
|
|
Article: /C O R R E C T I O N -- Par Pharmaceutical ...
PR Newswire;
May 22, 2006 ;
358 words
...In the news release, Patrick G. LePore Elected to Board of Directors of Par Pharmaceutical Companies, Inc., issued earlier today by Par Pharmaceutical Companies, Inc. over PR Newswire, we are advised by the company that the second sentence ...
|
|